Reference
- Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. Circulation 1994; 89(3): 1449–68
- Leclerc JR. Mechanisms of action of UFH and LMWH. In: Leclerc JR, ed. Venous thromboembolic disorders. Philadelphia: Lea & Febiger, 1991: 84–101
- Jordan RE, Oosta GM, Gardner WT, et al. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255(21): 10081–90
- Clagett GP, Anderson FA Jr, Heit J, et al. Prevention of venous thromboembolism. Chest 1995: 108(4 Suppl): 312–34S
- Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1995: 108(4 Suppl): 305–11S
- Cairns JA, Lewis HD Jr, Meade TW, et al. Antithrombotic agents in coronary artery disease. Chest 1995: 108(4 Suppl): 380–400S
- Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a standard care nomogram: a randomized controlled trial. Ann Intern Med 1993; 119(9): 874–81
- Andrew M, Johnston M. An approach to the infant with impaired he- mostasis. In: Thomson JM, ed. Blood coagulation and haemostasis: a practical guide. 4th ed. New York: Churchill Livingstone, 1991: 209–60
- Kitchen S, Preston FE. The ISI/INR system is an inappropriate model for heparin dosage monitoring using the APTT. Br J Haematol 1995; 89(Suppl 1): 50
- Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993: 119(2): 104–9
- Krulder JW, Van den Besselaar AM, Van der Meer FJ, et al. Diurnal changes in heparin effect during continuous constant-rate infusion: a study in nine patients with venous thromboembolism. J Intern Med 1994; 235(5): 411–7
- Leclerc JR. Role of the coagulation laboratory in evaluating patients with venous thromboembolism. In: Leclerc,2 pp 17–36
- Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995: 108(4 Suppl): 258–75S
- Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1995: 108(4 Suppl): 276–90S
- Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152(8): 1589–95
- Warkentin TE, Kehon JG. Heparin and platelets. Hematol Oncol Clin North Am 1990; 4(1): 243–64
- Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69(4): 344–50
- Stewart MW, Etches WS, Boshkov LK, et al. Heparin-induced thrombocytopenia: an improved method of detection based on lumi- aggregometry. BrJ Haematol 1995; 91(1): 173–7
- BarrowdifiFe TW. Low molecular weight heparin(s). BrJ Haematol 1995; 90(1): 1–7